Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
359 CHF | -1.64% | -6.39% | +18.48% |
Apr. 16 | Ypsomed Partners with ten23 health for Wearable Injector Product Commercialization | MT |
Apr. 12 | Dental Equipment Company Straumann Names New Chair | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 64.83 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.32% | 5.47B | B- | ||
-2.25% | 187B | C+ | ||
-1.32% | 108B | C | ||
-3.92% | 67.71B | A | ||
+7.99% | 53.07B | B- | ||
+15.74% | 47.36B | B- | ||
+6.01% | 39.73B | B+ | ||
+10.81% | 28.56B | A- | ||
+2.34% | 26.55B | B | ||
+15.97% | 25.13B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- YPSN Stock
- Ratings Ypsomed Holding AG